Literature DB >> 9455889

Enhancement of antibody-dependent cellular cytotoxicity of neonatal cells by interleukin-2 (IL-2) and IL-12.

Q H Nguyen1, R L Roberts, B J Ank, S J Lin, C K Lau, E R Stiehm.   

Abstract

Newborn infants are more susceptible to infections due in part to deficiencies in the cytotoxic functions of their lymphocytes. We investigated the ability of interleukin-2 (IL-2) and IL-12 to enhance the cytotoxicity of neonatal (cord blood) and adult mononuclear cells (MNCs) in both natural killer (NK) cell and antibody-dependent cellular cytotoxicity (ADCC) assays. The cytotoxic activity of cord blood MNCs was less than 50% that of adult MNCs in most assays prior to exposure to cytokines. Incubation with IL-2 (100 U/ml) or IL-12 (1 ng/ml) for 18 h increased the NK cell activity (using K562 target cells) of both cord blood and adult MNCs, and the combination of IL-2 and IL-12 increased cord blood cytotoxicity threefold, making the cytotoxicity of cord blood cells equivalent to that of adult cells treated with the same cytokines. In ADCC assays with chicken erythrocyte targets, the combination of IL-2 and IL-12 increased the cytotoxicities of both cord blood and adult MNCs, with greater enhancement again seen with cord blood cells. In assays with NK cell-resistant CEM cells coated with human immunodeficiency virus (HV) gp120 antigen in the presence of hyperimmune anti-HIV immunoglobulin, ADCC of cord blood MNCs was about 50% that of adult MNCs; ADCC of cord blood MNCs increased two- to threefold with the addition of IL-2 and IL-12, whereas ADCC of adult MNCs did not increase. Incubation of cord blood cells, but not adult cells, with IL-2 or IL-12 for 1 week increased the percentage of CD16+/CD56+ cells two- to fivefold and enhanced ADCC activity. Thus, IL-2 and IL-12 greatly enhance both the NK cell and ADCC activities of neonatal MNCs and increase the number of NK cells in longer-term culture.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9455889      PMCID: PMC121400          DOI: 10.1128/CDLI.5.1.98-104.1998

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  51 in total

1.  Decreased production of interferon-gamma by human neonatal cells. Intrinsic and regulatory deficiencies.

Authors:  C B Wilson; J Westall; L Johnston; D B Lewis; S K Dower; A R Alpert
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

2.  The production of soluble and cellular interleukin-2 receptors by cord blood mononuclear cells following in vitro activation.

Authors:  D L Nelson; C C Kurman; M E Fritz; B Boutin; L A Rubin
Journal:  Pediatr Res       Date:  1986-02       Impact factor: 3.756

3.  Interleukin-2 augments natural killer cell activity.

Authors:  C S Henney; K Kuribayashi; D E Kern; S Gillis
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

4.  Impaired neonatal natural killer-cell activity to herpes simplex virus: decreased inhibition of viral replication and altered response to lymphokines.

Authors:  P J Leibson; M Hunter-Laszlo; G S Douvas; A R Hayward
Journal:  J Clin Immunol       Date:  1986-05       Impact factor: 8.317

5.  Reduced expression of the interleukin-2-receptor gamma chain on cord blood lymphocytes: relationship to functional immaturity of the neonatal immune response.

Authors:  H Zola; M Fusco; H Weedon; P J Macardle; J Ridings; D M Roberton
Journal:  Immunology       Date:  1996-01       Impact factor: 7.397

6.  Differential effects of recombinant human interferon-gamma and interleukin 2 on natural killer cell activity of peripheral blood in early human development.

Authors:  Y Ueno; T Miyawaki; H Seki; A Matsuda; K Taga; H Sato; N Taniguchi
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

7.  Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood.

Authors:  H Seki; Y Ueno; K Taga; A Matsuda; T Miyawaki; N Taniguchi
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

8.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

9.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.

Authors:  J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

10.  Response of resting human peripheral blood natural killer cells to interleukin 2.

Authors:  G Trinchieri; M Matsumoto-Kobayashi; S C Clark; J Seehra; L London; B Perussia
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

View more
  7 in total

1.  Synergistic effect of interleukin-2 and a vaccine of irradiated melanoma cells transfected to secrete staphylococcal enterotoxin A.

Authors:  David P Schrayer; Nicola Kouttab; Vincent J Hearing; Harold J Wanebo
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

2.  Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.

Authors:  D Flieger; A S Hoff; T Sauerbruch; I G Schmidt-Wolf
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

Review 3.  NK cell-based immunotherapies in Pediatric Oncology.

Authors:  Kimberly A McDowell; Jacquelyn A Hank; Kenneth B DeSantes; Christian M Capitini; Mario Otto; Paul M Sondel
Journal:  J Pediatr Hematol Oncol       Date:  2015-03       Impact factor: 1.289

4.  Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection.

Authors:  S J Lin; R L Roberts; B J Ank; Q H Nguyen; E K Thomas; E R Stiehm
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

5.  The newborn human NK cell repertoire is phenotypically formed but functionally reduced.

Authors:  Dara M Strauss-Albee; Emily C Liang; Thanmayi Ranganath; Natali Aziz; Catherine A Blish
Journal:  Cytometry B Clin Cytom       Date:  2016-11-08       Impact factor: 3.058

6.  Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma.

Authors:  Jun Kurai; Hiroki Chikumi; Kiyoshi Hashimoto; Miyako Takata; Takanori Sako; Kosuke Yamaguchi; Naoki Kinoshita; Masanari Watanabe; Hirokazu Touge; Haruhiko Makino; Tadashi Igishi; Hironobu Hamada; Seiji Yano; Eiji Shimizu
Journal:  Int J Oncol       Date:  2012-08-24       Impact factor: 5.650

7.  Affinity-purified respiratory syncytial virus antibodies from intravenous immunoglobulin exert potent antibody-dependent cellular cytotoxicity.

Authors:  Nimesh Gupta; Jerome LeGoff; Soulaima Chamat; Severine Mercier-Delarue; Olivier Touzelet; Ultan F Power; Michel D Kazatchkine; Francois Simon; Sebastien Lacroix-Desmazes; Jagadeesh Bayry; Srinivas V Kaveri
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.